ArticleClinical, cosmetic and investigational dermatology2023

Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study.

Angelo Ruggiero et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.